安道药业

Homepage

About Us

Scientific Research

News Center

Join Us

Develop innovative pharmaceuticals
by leveraging the body’s oxygen-sensing mechanisms

Learn More

Extending the Nobel Prize-winning mechanism
to drive advances in life sciences

Corporate Vision：
Cherish humanity
respect science
benefit patients worldwide

A biopharmaceutical company
dedicated to the research of
hematological and oncological drugs

Founded in 2014, Hangzhou Kind Pharmaceutical Co., Ltd. is a biopharmaceutical company focusing on novel therapeutics for hematological diseases and oncology. Upholding the mission Cherish Humanity, Respect Science, Benefit Patients, we strive to address unmet clinical needs. Our high-value pipeline comprises AND017 for CKD-related anemia, BBB-permeable oral SERD AND019 for ER+/HER2- breast cancer, AND021 for renal carcinoma, and a portfolio of innovative next-generation ADC candidates.

Learn More

2014

Year of Establishment

Platform Technology

1.33

hectares

Corporate Campus

Patent Portfolio

Research
Field

We develop innovative, high-efficacy and low-toxic targeted and immune therapeutics for hematological and oncological disorders including CKD anemia, breast cancer and leukemia. Leveraging advanced molecular biology and clinical translation capabilities, we accelerate the delivery of safer, better treatments to improve patient outcomes worldwide.

Learn More

R&D Pipeline

Centered on unmet clinical needs, we have established a tiered R&D pipeline covering anemia and oncology, spanning preclinical to late-stage clinical development. All candidates are independently self-developed from target discovery to preclinical research. Our core technologies hold valid patents in China and the US, forming a sound global IP system to protect our international commercial rights.

Learn More

Research Field

R&D Pipeline